

**Sepsis: Recognition, diagnosis and early management guideline (update)
post-consultation meeting minutes**

Sepsis: recognition, diagnosis and early management – Post-Consultation Meeting

Date: 11/12/2023

Location: Virtual

Minutes: Final

Committee members present:		
Ann Hoskins (Chair)		Present for notes 1 – 6
Mervyn Singer (Topic Adviser)		Present for notes 1 – 6
Samina Begum		Present for notes 1 – 6
Tumena Corah		Present for notes 1 – 6
Peter Gosling		Present for notes 1 – 6
Alasdair Gray		Present for notes 1 – 6
Tessa Lewis		Present for notes 1 – 6
Marlies Ostermann		Present for notes 1 – 6
Mervyn Singer		Present for notes 1 – 6
Sally Wood		Present for notes 1 – 6

In attendance:		
Astrid Aregui (AA)	Medical Editor	Present for notes 1 – 6
Martin Allaby (MA)	Consultation Clinical Adviser	Present for notes 1 – 6
Victoria Axe	Guideline Commissioning Manager	Present for notes 1 – 6
Lindsay Claxton (LC)	Technical Adviser, Health Economics	Present for notes 1 – 6
Anthony Gildea (AG)	Technical Analyst	Present for notes 1 – 6
James Hall (JH)	Senior Content Designer	Present for notes 1 – 6
James Jagroo (JJ)	Senior Technical Analyst	Present for notes 1 – 6
Jon Littler (JL)	Project Manager	Present for notes 1 – 6
Emma McFarlane (EM)	Technical Adviser	Present for notes 1 – 6

Apologies:	
Louise Bradbury	Committee Member
Savio Fernandes	Committee Member
Jeremy Henning	Committee Member
Erum Khan	Committee Member
Barry Murphy-Jones	Committee Member
Giovanni Satta	Committee Member

Sepsis: Recognition, diagnosis and early management guideline (update) post-consultation meeting minutes

1. Welcome and objectives for the meeting

The Chair (AH) welcomed the committee members and NICE attendees to the post-consultation guideline committee meeting for the Sepsis update.

AH then outlined the objectives of the meeting before asking all committee members to verbally declare any interests that have arisen since the last meeting. No new interests were declared.

Finally, AH asked that the committee review the minutes from the previous meeting. The committee agreed they were an accurate record of the previous meeting's discussion.

2 – 5. Addressing stakeholder comments

The discussion sessions for the day were broken into four 90 minutes segments. AH introduced Emma McFarlane (EM), the Technical Adviser, James Jagroo (JJ), the Senior Technical Analyst, Anthony Gildea (AG) the Technical Analyst and Martin Allaby (MA) the Clinical Adviser. Led by EM, the development team presented the stakeholder comments we had received during the autumn consultation. These were divided up into broad themes for discussion and the development team had begun to draft responses for the committee to review and adjust.

The committee offered their opinions on the comments we'd received and how either the guideline might be altered in light of them, and/or how the comment may be responded to.

The Chair thanked the committee for their support, and the development team in all the work they'd done in preparing these comments for the committee and moved on to the final item on the agenda.

6. AOB, Summary and next steps

JL advised the committee of the next steps, confirming that they would have the revised recommendations from the day for review on Monday 18 December 2023. He also reminded them that the next stage of sepsis development was due to begin with the scoping and protocol review meeting on Tuesday 9 January 2024.

AH thanked everyone for their attendance and contributions and closed the meeting.

Date of next meeting: 9 January 2024

Location of next meeting: Virtual